The week has started with four massive biotech deals. 

Here's the breakdown:

Horizon Pharma will buy all outstanding shares of Hyperion Therapeutics for $46 per share in cash, or about $1.1 billion. The deal will expand Horizon's portfolio of drugs for a rare metabolic disease, according to a statement. Cellular Dynamics International has agreed to be acquired by Tokyo-based FujiFilm Holdings for $16.50 a share or about $307 million, the companies announced Monday. Cellular Dynamics is "a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications," and had revenues of $16.7 million in the 2014 financial year. It surged by as much as 111% in pre-market trading. Teva Pharmaceuticals will acquire Auspex Pharmaceuticals at $101 per share in cash. "The acquisition of Auspex is a significant step in strengthening Teva’s leadership position in [the Central Nervous System franchise] and advances us into underserved movement disorder markets," the companies said in a statement.
And finally, UnitedHealth will combine its pharmacy benefits unit with Catamaran Corp. to form a new competitor in the industry. UnitedHealth will buy out Catamaran for $61.50 per share in cash. 

After an ugly selloff last week, the iShares Nasdaq Biotechnology ETF is over 1% higher in pre-market trading. 

On Friday, Citi analysts laid out some compelling arguments for why biotechs are in a bubble, and then concluded that it is not.

The industry is in a new era where actual earnings and profits accompany the "hopes and dreams" that their inventions are usually associated with.

See Also:

Citi thinks pharmaceutical giant Teva is set for a 'material, potentially transformative, transaction'Here's what the rally in biotechs looks like compared to the tech bubbleAnalyst says Biogen has been 'wild-fun,' but it's time to take a break